Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
AssigneeInnate Pharma
InventorsStéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
Life of this patent
Estimating the term…
Abstract
The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
Claims13
An antibody or antibody fragment that binds a human CD39 polypeptide and that is capable of inhibiting the ATPase activity of a soluble extracellular domain human CD39 polypeptide, wherein the antibody or antibody fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 31 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NOS:
- 36 or 37.
An antibody or antibody fragment, wherein the antibody or antibody fragment comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 38 and a light chain comprising the amino acid sequence of SEQ ID NO:
- 39.
An antibody or antibody fragment, wherein the antibody or antibody fragment comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 38 and a light chain comprising the amino acid sequence of SEQ ID NO:
- 40.
Dependencies are inferred from the claim text.